Single-drug Chemotherapy Plus Immunotherapy in Metastatic Non-small Cell Lung Cancer Elderly Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

February 1, 2024

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2027

Conditions
Elderly PatientsMetastatic Lung Cancer
Interventions
DRUG

Single drug chemotherapy plus immunotherapy

The choice of chemotherapy plus immunotherapy for squamous cell carcinoma is gemcitabine or paclitaxel or vinorelbine. Paclitaxel or pemetrexed are available for monotherapy for non-squamous and non-small cell lung cancer. Immunotherapy drugs can be Pembrolizumab /Penpulimab/ Camrelizumab/ Tislelizumab / Sintilimab/ sulgarizumab and so on

Trial Locations (1)

430079

RECRUITING

Hubei Cancer Hospital, Wuhan

All Listed Sponsors
lead

Hubei Cancer Hospital

OTHER